Ulrika Harmenberg

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: ACTA ONCOLOGICA. 2019;58(3):306-312

Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres.

Stenman M; Staehler M; Szabados B; Sandström P; Laurell A; Lindskog M; Harmenberg U
Article: CANCER MANAGEMENT AND RESEARCH. 2019;11:1289-1297

Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis.

Redig J; Dalén J; Harmenberg U; Lindskog M; Ljungberg B; Lundstam S; Sandin R; Wahlgren T; Åkerborg Ö; Jakobsson M
Article: BRITISH JOURNAL OF CANCER. 2018;119(7):840-846

A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis.

Sjöberg E; Frödin M; Lövrot J; Mezheyeuski A; Johansson M; Harmenberg U; Egevad L; Sandström P; Östman A
Article: RADIOTHERAPY AND ONCOLOGY. 2018;127(3):501-506

Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014.

Stenman M; Sinclair G; Paavola P; Wersäll P; Harmenberg U; Lindskog M
Article: EUROPEAN UROLOGY. 2017;72(3):368-376

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.

Escudier B; Motzer RJ; Sharma P; Wagstaff J; Plimack ER; Hammers HJ; Donskov F; Gurney H; Sosman JA; Zalewski PG; Harmenberg U; McDermott DF; Choueiri TK; Richardet M; Tomita Y; Ravaud A; Doan J; Zhao H; Hardy H; George S
Article: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2017;35(9):541.e15-541.e22

Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations.

Lindskog M; Wahlgren T; Sandin R; Kowalski J; Jakobsson M; Lundstam S; Ljungberg B; Harmenberg U
Article: ONCOIMMUNOLOGY. 2017;6(8):e1338238

Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer.

Sarhan D; Leijonhufvud C; Murray S; Witt K; Seitz C; Wallerius M; Xie H; Ullén A; Harmenberg U; Lidbrink E; Rolny C; Andersson J; Lundqvist A
Article: BRITISH JOURNAL OF CANCER. 2017;116(2):195-201

Perivascular PDGFR-β is an independent marker for prognosis in renal cell carcinoma.

Frödin M; Mezheyeuski A; Corvigno S; Harmenberg U; Sandström P; Egevad L; Johansson M; Östman A
Article: WORLD JOURNAL OF UROLOGY. 2016;34(8):1081-1086

Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study.

Dabestani S; Thorstenson A; Lindblad P; Harmenberg U; Ljungberg B; Lundstam S
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2016;50(1):2-8

Impact of quality indicators on adherence to National and European guidelines for renal cell carcinoma.

Thorstenson A; Harmenberg U; Lindblad P; Ljungberg B; Lundstam S; Swedish Kidney Cancer Quality Register Group
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2015;373(19):1814-1823

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee J-L; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DYC; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ; METEOR Investigators
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2015;373(19):1803-1813

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Motzer RJ; Escudier B; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Choueiri TK; Gurney H; Donskov F; Bono P; Wagstaff J; Gauler TC; Ueda T; Tomita Y; Schutz FA; Kollmannsberger C; Larkin J; Ravaud A; Simon JS; Xu L-A; Waxman IM; Sharma P; CheckMate 025 Investigators
Article: BIOMED RESEARCH INTERNATIONAL. 2015;2015:456040-5

Cancer Characteristics and Current Treatments of Patients with Renal Cell Carcinoma in Sweden.

Thorstenson A; Harmenberg U; Lindblad P; Holmström B; Lundstam S; Ljungberg B
Article: BMC CANCER. 2014;14:408

Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.

Farnebo J; Grybäck P; Harmenberg U; Laurell A; Wersäll P; Blomqvist LK; Ullén A; Sandström P
Article: PROSTATE CANCER AND PROSTATIC DISEASES. 2014;17(1):81-90

An expression signature at diagnosis to estimate prostate cancer patients' overall survival.

Peng Z; Skoog L; Hellborg H; Jonstam G; Wingmo I-L; Hjälm-Eriksson M; Harmenberg U; Cedermark GC; Andersson K; Ahrlund-Richter L; Pramana S; Pawitan Y; Nistér M; Nilsson S; Li C
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2013;369(8):722-731

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
Article: BRITISH JOURNAL OF CANCER. 2013;108(7):1541-1549

Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008).

Wahlgren T; Harmenberg U; Sandström P; Lundstam S; Kowalski J; Jakobsson M; Sandin R; Ljungberg B
Article: LANCET ONCOLOGY. 2013;14(2):117-124

2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.

Kellokumpu-Lehtinen P-L; Harmenberg U; Joensuu T; McDermott R; Hervonen P; Ginman C; Luukkaa M; Nyandoto P; Hemminki A; Nilsson S; McCaffrey J; Asola R; Turpeenniemi-Hujanen T; Laestadius F; Tasmuth T; Sandberg K; Keane M; Lehtinen I; Luukkaala T; Joensuu H; PROSTY study group
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2013;42(1):109-117

Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.

Cortés-González JR; Castellanos E; Sandberg K; Eriksson M-H; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner K-M; Nilsson S
Article: BJU INTERNATIONAL. 2011;108(5):665-672

Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.

Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
Article: LAKARTIDNINGEN. 2011;108(22-23):1248-1249

[Kidney care--a web-based registry tool and decision support. Good for follow up and therapy evaluation in metastazing renal cancer].

Harmenberg U; Wersäll P; Sandström P
Article: ACTA ONCOLOGICA. 2011;50 Suppl 1:98-103

Curative radiation therapy in prostate cancer.

Harmenberg U; Hamdy FC; Widmark A; Lennernäs B; Nilsson S
Article: PROTEOMICS. 2008;8(11):2211-2219

Detection of pancreatic cancer using antibody microarray-based serum protein profiling.

Ingvarsson J; Wingren C; Carlsson A; Ellmark P; Wahren B; Engström G; Harmenberg U; Krogh M; Peterson C; Borrebaeck CAK
Article: ACTA ONCOLOGICA. 2005;44(6):644-650

Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.

Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
Article: ACTA ONCOLOGICA. 2005;44(5):490-495

Prostate cancer cell lines lack amplification: overexpression of HER2.

Ullén A; Lennartsson L; Harmenberg U; Lennernäs B; Majumder K; Holmberg AR; Nilsson S; Elmberger GP
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2002;51(4):209-218

Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma.

Mosolits S; Steinitz M; Harmenberg U; Ruden U; Eriksson E; Mellstedt H; Fagerberg J
Article: INTERNATIONAL JOURNAL OF CANCER. 1999;80(5):671-680

T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma.

Fagerberg J; Yi Q; Gigliotti D; Harmenberg U; Rudén U; Persson B; Osterborg A; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 1999;47(6):315-320

Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma.

Mosolits S; Harmenberg U; Rudén U; Ohman L; Nilsson B; Wahren B; Fagerberg J; Mellstedt H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;58(1):5-13

Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).

Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Visa fler

Alla övriga publikationer

Editorial comment: JOURNAL OF UROLOGY. 2013;189(6):2107-2108

Re: Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.

Taneja SS
Published paper: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(25):4068-4075

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI